Rhumbline Advisers Summit Therapeutics Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 128,619 shares of SMMT stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128,619
Previous 140,643
8.55%
Holding current value
$2.69 Million
Previous $582,000
72.34%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SMMT
# of Institutions
148Shares Held
66.2MCall Options Held
1.05MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$485 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$184 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$86.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$61.9 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.2B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...